Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
**Background:** Patients with advanced or recurrent endometrial cancer (EC) typically have limited treatment options and poor long-term survival outcomes following first-line therapy. Real-world treatment patterns and survival outcomes data are limited for patients in this setting. **Objectives:**...
Saved in:
Main Authors: | Robert L. Coleman, Jamie Garside, Jean Hurteau, Joehl Nguyen, Monica Kobayashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2023-10-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.87853 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
by: Monica Kobayashi, et al.
Published: (2023-11-01) -
Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm
by: Scott Goulden, et al.
Published: (2023-09-01) -
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01) -
Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
by: Yinfang Gu, et al.
Published: (2025-02-01) -
Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations
by: Sophia Kreft, et al.
Published: (2025-01-01)